Medpace Q3 2026 Earnings: The $716M Quarter That Ran on Client Cash
Medpace Q3 2026 revenue rose 8.5% to $716.0M with a 19.2% net margin; diluted EPS jumped 25.4% to $4.84 on operating leverage and a lower tax rate.
#medpace
Medpace
Financial analysis and earnings reports for Medpace Holdings, Inc. (MEDP), the Cincinnati-based clinical contract research organization (CRO) running Phase I-IV trials with strength in oncology, metabolic disease and central nervous system